Freedom Lawyers of America

A site that will chronical the dark side of the news to show what happens when freedom is dying and to sell his books SHELLY WAXMAN'S BOOKS. We also foster and certify the proper use of independent contractors. http:independentcontractor.info CHECK OUR WEBSITE http://thelawyer.info WHERE YOU CAN ALSO ACCESS OUR FREEDOM LAWYERS YAHOO GROUP

Wednesday, March 10, 2004

Fw: Why the "munchies"? Here's one thing they found ...

----- Original Message -----
From: "R. J. Tavel, J.D."
To: "Learning Electronically About Freedom mailing service"

Sent: Wednesday, March 10, 2004 10:23 AM
Subject: Why the "munchies"? Here's one thing they found ...

> GET ALL THE BREAKING LEGAL NEWS ALL THE TIME at
> http://freedomlaw.com/LNEWSUPD.html
> updated every 15 minutes on the coffee table at Freedomlaw.com
> http://freedomlaw.com/coffee.html
> ______________________________________________________
> Single pill tackles smoking and obesity
> http://news.independent.co.uk/uk/health/story.jsp?story=499658
>
> A single pill that tackles obesity and smoking could become the next
> pharmaceutical industry blockbuster after scientists revealed its first
> results yesterday.
>
> Rimonabant, made by the French company Sanofi-Synthelabo, has been shown
in
> two separate American trials to speed weight loss in overweight patients
> and to double the number of people stopping smoking while preventing
> subsequent weight gain.
>
> The twin effects of rimonabant on two of the Western world's dominant
> cravings could give it a crucial advantage over other drugs on the market.
> Preventing weight gain after giving up smoking would remove one of the
> greatest disincentives for those trying to kick the habit.
>
> Rimonabant is involved in seven trials in more than 13,000 patients around
> the world. It works by blocking cannabis receptors in the brain and was
> discovered after researchers decided to investigate why cannabis smokers
> developed the "munchies", the fierce appetite that often accompanies
> smoking of the drug.
>
> First results presented to the American College of Cardiology meeting in
> New Orleans yesterday showed that among 1,036 overweight patients treated
> for a year in Canada, those given the highest dose of rimonabant lost an
> average of 8.6kg (1st 5lb), compared with 2.3kg (5lb) for those on
placebos.
>
> In a second trial in 787 heavy smokers treated for 10 weeks in the US, 36
> per cent of those given rimonabant had stopped smoking, compared with 20
> per cent of those on placebo. Those on the drug, brand name Acomplia, lost
> half a pound weight on average, while those on placebos gained 2.5lb.
>
> Robert Anthenelli, one of the lead researchers in the second trial from
the
> University of Cincinnati College of Medicine, said: "Since these two
> studies show that rimonabant treats obesity and related metabolic
disorders
> in overweight and obese patients, and also helps people quit smoking
> without significant post-cessation weight gain, we may have a very
> promising new approach for managing two major and preventable risk factors
> for cardiovascular disease with one and the same drug."
>
> British experts welcomed the results. Ian Campbell, chairman of the
> National Obesity Forum, described the findings as "very positive" . "To
> achieve an 8kg weight loss over one year is as good as other medications
> that are available," he said. "I would look forward to the two-year
results
> because once you have got weight down maintaining weight loss is crucial.
> If it can prevent weight gain in people who stop smoking that could be its
> unique selling point."
>
> Professor Martin Jarvis, an expert on smoking at University College
London,
> said: "These are encouraging results. I know people are excited about it.
> For years everyone has been searching for a drug that is effective in
> reducing weight and doesn't have nasty side-effects. Lowered weight gain
> after stopping smoking would be an added bonus. Given how obesity is
> galloping away it must have a potentially really big market."
>
> Rimonabant is the first of a new class of drugs called selective CB1
> blockers which act on the addictive pathway in the brain associated with
> regulating the body's intake of food and tobacco dependency. Research
> suggests the drug taps into pathways associated with the pleasure obtained
> by eating, smoking tobacco or smoking cannabis. CB1 receptors are also
> found in fat cells and have a role in fat and glucose metabolism.
>
> The drug is expected to be on the market in the UK next year.
>

posted by FLoA # 3/10/2004 10:40:46 AM

<< Home